Matthew Korenberg
2016
In 2016, Matthew Korenberg earned a total compensation of $2M as Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 30% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $118,500 |
|---|---|
| Option Awards | $797,704 |
| Salary | $378,750 |
| Stock Awards | $664,015 |
| Other | $7,872 |
| Total | $1,966,841 |
Korenberg received $797.7K in option awards, accounting for 41% of the total pay in 2016.
Korenberg also received $118.5K in non-equity incentive plan, $378.8K in salary, $664K in stock awards and $7.9K in other compensation.
Rankings
In 2016, Matthew Korenberg's compensation ranked 4,961st out of 14,075 executives tracked by ExecPay. In other words, Korenberg earned more than 64.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,961 out of 14,075 | 65th |
Division Manufacturing | 1,774 out of 5,489 | 68th |
Major group Chemicals And Allied Products | 561 out of 1,895 | 70th |
Industry group Drugs | 417 out of 1,538 | 73rd |
Industry Pharmaceutical Preparations | 332 out of 1,176 | 72nd |
Source: SEC filing on April 14, 2017.
Korenberg's colleagues
We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2016.